INT224046

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 12
Disease Relevance 4.00
Pain Relevance 3.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Adora2b) plasma membrane (Adora2b) signal transducer activity (Adora2b)
Anatomy Link Frequency
corpus 1
epithelial cells 1
jugular vein 1
kidney 1
Adora2b (Mus musculus)
Pain Link Frequency Relevance Heat
adenocard 685 100.00 Very High Very High Very High
Potency 105 99.84 Very High Very High Very High
ischemia 285 99.82 Very High Very High Very High
agonist 714 99.80 Very High Very High Very High
cytokine 118 96.68 Very High Very High Very High
antagonist 170 94.96 High High
Inflammation 244 94.64 High High
Pain 8 73.28 Quite High
Neurotransmitter 8 72.64 Quite High
Central nervous system 8 71.92 Quite High
Disease Link Frequency Relevance Heat
Cv Unclassified Under Development 290 99.82 Very High Very High Very High
Erectile Dysfunction 8 96.60 Very High Very High Very High
Vasculogenic Impotence 4 95.12 Very High Very High Very High
INFLAMMATION 246 94.64 High High
Apoptosis 25 94.40 High High
Anaplastic Astrocytoma 12 92.16 High High
Asthma 327 89.60 High High
Alopecia 4 85.68 High High
Diabetes Mellitus 20 81.08 Quite High
Hypertension 8 80.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
After having shown that selective inhibition of the A2BAR attenuates renal protection by IP, we next pursued a potential therapeutic role of a specific A2BAR agonist (BAY 60–6583).
Negative_regulation (inhibition) of A2BAR associated with agonist
1) Confidence 0.43 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.48 Pain Relevance 0.36
For specific inhibition of the A2BAR, PSB1115 (Tocris, Biotrend-Chemikalien) was administered IV via the jugular vein (5 mg/kg/h).
Negative_regulation (inhibition) of A2BAR in jugular vein
2) Confidence 0.43 Published 2008 Journal PLoS Medicine Section Body Doc Link PMC2504049 Disease Relevance 0.19 Pain Relevance 0.07
In vitro, A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-?
Negative_regulation (receptors) of A2B in epithelial cells associated with adenocard
3) Confidence 0.41 Published 2008 Journal J Occup Med Toxicol Section Body Doc Link PMC2259400 Disease Relevance 0.57 Pain Relevance 0.20
Ischemic preconditioning protected all the mice from ischemia-induced loss of kidney function except the A2BAR?
Negative_regulation (loss) of A2BAR in kidney associated with ischemia
4) Confidence 0.38 Published 2008 Journal PLoS Medicine Section Abstract Doc Link PMC2504049 Disease Relevance 1.02 Pain Relevance 0.64
Endothelial dysfunction of human corpus cavernosum may be correlated with the loss of adenosine A2B ARs activity, indicating a possible employment of specific A2B AR agonists as anew therapeutic approach to manage severe vasculogenic impotence resistant to common vasodilators [59].
Negative_regulation (loss) of A2B in corpus associated with adenocard, agonist and vasculogenic impotence
5) Confidence 0.35 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 1.13 Pain Relevance 0.41
Substitution at the paraposition of the phenyl ring with a halogen atom led to a two- to fourfold loss of A2B AR activity in comparison with the unsubstituted phenyl derivative 7 (EC50 hA2B?
Negative_regulation (loss) of A2B
6) Confidence 0.26 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0 Pain Relevance 0.18
Elongation or branching of the 2-alkyl spacer proved to weaken the affinity against all ARs. 2-Indolyl derivative decreased markedly A2B AR potency compared with 3-indolyl analogues, revealing that altered connectivity failed to improve the binding profile of the series (data not shown).
Negative_regulation (decreased) of A2B associated with potency
7) Confidence 0.26 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0.05 Pain Relevance 0.33
A2B ARs have been generally defined as the “low-affinity ARs,” as their lower affinity for the endogenous ligand, adenosine, and for some typical agonists, such as 5?
Negative_regulation (defined) of A2B associated with adenocard and agonist
8) Confidence 0.26 Published 2008 Journal Purinergic Signal Section Body Doc Link PMC2583210 Disease Relevance 0.26 Pain Relevance 0.64
Since receptor trafficking may play a role in this cross-desensitization process, this effect may contribute to the desensitization and subsequent downregulation of the A2BR [81].
Negative_regulation (downregulation) of A2BR
9) Confidence 0.18 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2245999 Disease Relevance 0.14 Pain Relevance 0.20
The role of GRK2 in agonist-induced phosphorylation and subsequent desensitization of A2AR and A2BR was thoroughly investigated by Kelly and co-workers.
Negative_regulation (desensitization) of A2BR associated with agonist
10) Confidence 0.15 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2245999 Disease Relevance 0 Pain Relevance 0.16
treatment appeared to markedly reduce agonist-dependent receptor phosphorylation and also attenuated agonist-mediated A2BR desensitization.
Negative_regulation (desensitization) of A2BR associated with agonist
11) Confidence 0.15 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2245999 Disease Relevance 0.09 Pain Relevance 0.26
M) desensitization of the A2BR by 50% [60].
Negative_regulation (desensitization) of A2BR
12) Confidence 0.15 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2245999 Disease Relevance 0.06 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox